Last November, an employee at Intas Pharmaceuticals, which makes several widely used chemotherapies that are in short supply, was seen pouring acetic acid in a trash bin containing documents at a manufacturing facility.
Another employee failed to report all test results on product samples and, at times, printouts were tossed in the trash. Plastic bags filled with torn and discarded important production records were stashed under a stairwell and on a truck parked outside. Laboratory data, in some cases, went missing. The company also failed to validate processes to ensure strength, quality and purity of its medicines.
These serious violations of manufacturing protocols were revealed in a July 28 warning letter sent by the U.S. Food and Drug Administration in response to an inspection late last year at the Intas facility in Sanand, India. Some details were previously disclosed in an FDA inspection report made public, but the letter provides added information and context about agency concerns.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect